FDA inspection
GlaxoSmithKline: FDA inspection ending Feb 2, 2000
FDA inspection 11981 · No Action Indicated (NAI) · Durham, NC
Key facts
| Inspection ID | 11981 |
|---|---|
| Firm | GlaxoSmithKline |
| FEI number | 1000112035 |
| Address | 2525 Whilden Dr |
| City | Durham |
| State | NC |
| ZIP | 27713-1357 |
| Fiscal year | 2000 |
| Inspection end date | Feb 2, 2000 |
| Classification | No Action Indicated (NAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data